Publications by authors named "Graciela Cruz-Rico"

Claim this Profile
A
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Graciela Cruz-Rico

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
Luis Lara-Mejía, Andres F Cardona, Luis Mas, Claudio Martin, Suraj Samtani, Graciela Cruz-Rico

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy.
Alberto Guijosa, Eduardo Rios-Garcia, David Dávila-Dupont, Graciela Cruz-Rico, Alessandro Russo

Lung Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Graciela Cruz-Rico

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI.
David Heredia, Laura Bolaño-Guerra, Angel Valencia-Velarde, Edgar Varela Santoyo, Luis Lara-Mejía, Graciela Cruz-Rico

Cancer Biomark· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.
Juan-Manuel Hernandez-Martinez, Alberto Guijosa, Diana Flores-Estrada, Graciela Cruz-Rico, Jenny Turcott

JCO Glob Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC.
Luis Lara-Mejía, Andres F Cardona, Luis Mas, Claudio Martin, Suraj Samtani, Graciela Cruz-Rico

J Thorac Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer.
Alejandro Avilés-Salas, Diana Flores-Estrada, Luis Lara-Mejía, Rodrigo Catalán, Graciela Cruz-Rico

Thorac Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
David Heredia, Luis Mas, Andres F Cardona, Víctor Oyervides, Rodrigo Motta Guerrero, Graciela Cruz-Rico

Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Graciela Cruz-Rico, Alejandro Avilés-Salas, Xitlally Popa-Navarro, Luis Lara-Mejía, Rodrigo Catalán

Pathol Oncol Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors.
Mario Orozco-Morales, Alejandro Avilés-Salas, Norma Hernández-Pedro, Rodrigo Catalán, Graciela Cruz-Rico

J Immunol Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
Zyanya Lucia Zatarain-Barrón, Andrés F Cardona, Diego Díaz-García, Rogelio Trejo Rosales, Leonardo Rojas, Graciela Cruz-Rico

Oncology· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.
Oscar Arrieta, Alejandro Aviles-Salas, Mario Orozco-Morales, Norma Hernández-Pedro, Andrés F Cardona, Graciela Cruz-Rico

Cancer Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Oscar Arrieta, Laura-Alejandra Ramírez-Tirado, Enrique Caballé-Perez, Alberto Mejia-Perez, Zyanya Lucia Zatarain-Barrón, Graciela Cruz-Rico

Thorac Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Oscar Arrieta, Feliciano Barrón, Miguel-Ángel Salinas Padilla, Alejandro Avilés-Salas, Laura Alejandra Ramírez-Tirado, Graciela Cruz-Rico

JAMA Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America.
Oscar Arrieta, Andrés F Cardona, Guillermo Bramuglia, Graciela Cruz-Rico, Luis Corrales

Oncology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Assessment of Ga-DOTA-E-[c(RGDfK)] PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel.
Oscar Arrieta, Francisco O Garcia-Perez, David Michel-Tello, Laura-Alejandra Ramírez-Tirado, Quetzali Pitalua-Cortes, Graciela Cruz-Rico

J Nucl Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer.
Graciela Cruz-Rico, Alejandro Avilés-Salas, Manuel Segura-González, Ana María Espinosa-García, Laura Alejandra Ramírez-Tirado

Am J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Oscar Arrieta, Graciela Cruz-Rico, Enrique Soto-Perez-de-Celis, Laura-Alejandra Ramírez-Tirado, Enrique Caballe-Perez

Target Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Personalized treatment in non-small cell lung cancer].
Alma Delia Campos-Parra, Graciela Cruz-Rico, Oscar Arrieta

Rev Invest Clin· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis